Insulin Costs and Use After the Inflation Reduction Act Out-of-Pocket Cap

The analysis reveals a significant shift in insulin cost and usage following the Inflation Reduction Act's $35 cap on out-of-pocket insulin costs. The data shows a notable decrease in financial burden for insulin users, especially those who previously faced high out-of-pocket expenses. This change is crucial as it addresses a long-standing issue for many diabetics, potentially improving adherence to insulin therapy and overall health outcomes. The findings underscore the importance of policy measures in making essential medications more accessible and affordable.